Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Stock Set to Reverse Split on Friday, July 31st

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) shares are set to reverse split before the market opens on Friday, July 31st. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, July 30th.

Calidi Biotherapeutics Price Performance

CLDI stock opened at $0.11 on Thursday. The firm has a 50 day moving average of $0.16 and a 200-day moving average of $0.44. Calidi Biotherapeutics has a 12-month low of $0.10 and a 12-month high of $10.92. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.04 million, a price-to-earnings ratio of -0.02 and a beta of 1.30.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.43) EPS for the quarter.

Institutional Trading of Calidi Biotherapeutics

Several large investors have recently bought and sold shares of CLDI. DRW Securities LLC purchased a new position in shares of Calidi Biotherapeutics in the fourth quarter valued at $173,000. Geode Capital Management LLC raised its stake in shares of Calidi Biotherapeutics by 41.7% during the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after buying an additional 12,334 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Calidi Biotherapeutics in the 4th quarter worth about $25,000. Institutional investors and hedge funds own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.